Clinical

This channel newsfeed includes clinical content on treating patients or the clinical implications in a variety of cardiac subspecialties and disease states. The channel includes news on cardiac surgery, interventional cardiology, heart failure, electrophysiology, hypertension, structural heart disease, use of pharmaceuticals, and COVID-19.

Cardiologist sparks fresh debate over mandatory vaccines
The cardiologist at the head of an influential CDC panel sees serious problems with modern vaccine policies. While many experts seem to disagree, one organization has jumped to his defense.
FDA shares update about CGM sensor recalls—issue now linked to 860 serious injuries
Abbott first warned the public about this problem in November. Now, for the second time in less than a month, the FDA is providing additional details.
Medtronic SVP Nina Goodheart to retire after nearly 20 years in cardiovascular care
Nina Goodheart, the president of Medtronic’s structural heart and aortic business, has announced her retirement.
Key trends in transcatheter tricuspid valve repair and replacement
The interventional treatment of tricuspid valve disease has evolved in recent years thanks to new research and critical FDA approvals. Cardiologist Ryan Kaple, MD, reviewed this trend for a new video interview.
Interventional cardiologists take on angiography-derived physiology in new expert opinion
ADP offers care teams multiple benefits not seen with traditional wire-based physiologic assessments. A roundtable of 17 expert clinicians discussed the topic at length, and their findings were used to develop a new manuscript published in JSCAI.

Cardiologist sparks fresh debate over mandatory vaccines

The cardiologist at the head of an influential CDC panel sees serious problems with modern vaccine policies. While many experts seem to disagree, one organization has jumped to his defense.

FDA shares update about CGM sensor recalls—issue now linked to 860 serious injuries

Abbott first warned the public about this problem in November. Now, for the second time in less than a month, the FDA is providing additional details.

Medtronic SVP Nina Goodheart to retire after nearly 20 years in cardiovascular care

Nina Goodheart, the president of Medtronic’s structural heart and aortic business, has announced her retirement.

Transcatheter treatment of tricuspid valve disease has rapidly evolved over the past two years, giving physicians new tools to address a condition long considered under treated due to limited procedural options and complex anatomy. Ryan K. Kaple, MD, FACC, FSCAI, director of the structural and congenital heart program at Hackensack University Medical Center, spoke top Cardiovascular Business about recent advances and his center's real-world experience.

Key trends in transcatheter tricuspid valve repair and replacement

The interventional treatment of tricuspid valve disease has evolved in recent years thanks to new research and critical FDA approvals. Cardiologist Ryan Kaple, MD, reviewed this trend for a new video interview.

Interventional cardiologists take on angiography-derived physiology in new expert opinion

ADP offers care teams multiple benefits not seen with traditional wire-based physiologic assessments. A roundtable of 17 expert clinicians discussed the topic at length, and their findings were used to develop a new manuscript published in JSCAI.

Pioneer heart surgeon Vinay Badhwar elected STS president

Badhwar is a longtime STS member and world leader in robotic technologies. In fact, he and his team recently launched a 40-part video series to help teach other clinicians about robotic-assisted cardiac surgery.

The Impella RP with SmartAssist. Image courtesy of Johnson & Johnson MedTech.

FDA warns that Johnson & Johnson heart pump sensors may malfunction—22 injuries reported

There is a risk of users making adjustments during treatment that are unnecessary. The FDA is still evaluating the issue at this time.

artificial intelligence money finance acquisition

Medtronic to acquire AI-enabled FFR specialists CathWorks for up to $585M

Medtronic has held a minority investment in CathWorks for several years, and the two organizations entered into a co-promotion agreement in 2022. Once finalized, the move will increase Medtronic's presence in the cath lab.